BIOMAT Database Logo BIOMAT Database Logo

Ritonavir-saquinavir rescue therapy in HIV-positive patients failing with indinavir, rotinavir or saquinavir. 1999

S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck

UI MeSH Term Description Entries
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016879 Salvage Therapy A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases. Salvage Treatment,Therapy, Salvage,Salvage Therapies,Salvage Treatments,Therapies, Salvage,Treatment, Salvage,Treatments, Salvage
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts
D019258 Saquinavir An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. Invirase,Ro 31-8959,Saquinavir Mesylate,Saquinavir Monomethanesulfonate,Saquinivir,Monomethanesulfonate, Saquinavir,Ro 31 8959,Ro 318959
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D019438 Ritonavir An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A. ABT 538,ABT-538,Norvir,ABT538

Related Publications

S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Nephropathy and renal colic in patients treated with indinavir, ritonavir plus indinavir or ritonavir plus saquinavir.
October 1999, AIDS (London, England),
S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
May 2001, AIDS (London, England),
S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure.
July 1998, AIDS (London, England),
S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
July 2000, AIDS (London, England),
S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
August 1997, Pharmacy world & science : PWS,
S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.
January 2001, Scandinavian journal of infectious diseases,
S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Patients failing saquinavir therapy require an early change to indinavir before HIV-1 viral load reaches high levels.
January 1999, Antiviral therapy,
S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.
January 2001, HIV clinical trials,
S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
February 2000, European journal of medical research,
S De Wit, and P Cassano, and P Hermans, and B Sommereijns, and K Kabeya, and E O'Doherty, and N Clumeck
Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
July 2004, Journal of clinical pharmacology,
Copied contents to your clipboard!